OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Brawer on the Prolaris Genetic Test in Predicting Prostate Cancer Aggressiveness

May 22nd 2017

Michael Brawer, MD, vice president of Medical Affairs, Myriad Genetic Laboratories, discusses the Prolaris genetic test in predicting prostate cancer aggressiveness in African-American men.

Dr. Lallas on Immunotherapy Combinations in Genitourinary Malignancies

May 22nd 2017

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses combinations of immunotherapy for genitourinary malignancies.

Dr. Greten on Promising Immunotherapy Agents in HCC

May 19th 2017

Tim F. Greten, MD, senior investigator thoracic and gastrointestinal oncology branch, head, gastrointestinal malignancy section, National Cancer Institute, discusses promising immunotherapy agents being investigated in hepatocellular carcinoma (HCC).

Dr. Catton on Quality Assurance for Radiation Therapy for Sarcoma

May 19th 2017

Charles Catton, MD, professor, Department of Radiation Oncology University of Toronto, discusses quality assurance with radiation therapy for patients with sarcoma.

Dr. Piccart Discusses Biomarkers in Early Breast Cancer

May 19th 2017

Martine J. Piccart, MD, PhD, professor, Université Libre de Bruxelles, director, Medicine Department, Institut Jules Bordet, discusses biomarkers in early breast cancer.

Challenges Facing the Future of Cholangiocarcinoma

May 19th 2017

Jesper Andersen, PhD, associate professor, Biotech and Innovation Centre, University of Copenhagen, discusses the challenges facing the future treatment of patients with cholangiocarcinoma.

Expert on Studies of the PSA Test in Prostate Cancer

May 19th 2017

Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center discusses studies of the controversial prostate-specific antigen (PSA) test for patients with prostate cancer.

Dr. Feldman on Active Surveillance in Younger Men with Prostate Cancer

May 19th 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of Surgery, Harvard Medical School, discusses a study focused on active surveillance in men with prostate cancer under the age of 60.

Dr. Petrylak on FDA Approval of Pembrolizumab in Bladder Cancer

May 18th 2017

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with bladder cancer.

Dr. Kumar Discusses Daratumumab in Multiple Myeloma

May 18th 2017

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses daratumumab in multiple myeloma.

Dr. Papa on Leukapheresis Manufacturing Approach in Head and Neck Cancer

May 18th 2017

Sophie Papa, PhD, MBBS, MRCP, medical oncologist, Clinical Academic Group, Department of Research Oncology, King’s College London, discusses leukapheresis manufacturing approach in head and neck cancer.

Dr. Kasper on Future Treatment Approaches in Sarcoma

May 17th 2017

Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, Mannheim, discusses future treatment approaches in the field of sarcoma and the potential role of imatinib (Gleevac).

Dr. Ansell on Promising Combinations Being Studied in MCL

May 17th 2017

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses promising combinations in the pipeline for mantle cell lymphoma (MCL).

Dr. Black on Combinations with Durvalumab in Bladder Cancer

May 17th 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses combination trials with durvalumab (Imfinzi) for patients with bladder cancer.

Dr. Gupta on VEGF Inhibitors Combined with Immunotherapy in Kidney Cancer

May 17th 2017

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses combining VEGF inhibitors with immunotherapy for patients with kidney cancer.

Dr. Begna on Recent Advancements in MPNs

May 16th 2017

Kebede H. Begna, MD, assistant professor of Medicine, Mayo Clinic, discusses some of the recent advancements in the field of myeloproliferative neoplasms (MPNs).

Dr. Nowakowski on Next Steps With Emerging Agents in MCL

May 16th 2017

Grzegorz S. Nowakowski, MD, an assistant professor of Medicine at Mayo Clinic, discusses the status of emerging agents moving through the pipeline of mantle cell lymphoma.

Dr. Strosberg Discusses Trials in Neuroendocrine Tumors

May 16th 2017

Jonathan Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses trials in neuroendocrine tumors (NETs).

Dr. O'Regan Discusses the Future of Treatment in HER2+ Breast Cancer

May 16th 2017

Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses the potential of future treatments for patients with HER2-positive breast cancer.

Dr. Campbell on the Guidelines for the Management of Kidney Cancer

May 16th 2017

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the recent guidelines for the management of patients with kidney cancer.